- A g-C3N4-based heterogeneous photocatalyst for visible light mediated aerobic benzylic C-H oxygenations
-
A metal-free heterogeneous photocatalytic system has been developed for highly efficient benzylic C-H oxygenations using oxygen as an oxidant. This visible light mediated oxidation reaction utilizes graphitic carbon nitride (g-C3N4) as a recyclable, nontoxic and low cost photocatalyst. Mild reaction conditions allow for the generation of synthetically and biologically valued isochromannones, phthalides, isoquinolinones, isoindolinones and xanthones from readily accessible alkyl aromatic precursors in good yields. The heterogeneous nature of the g-C3N4 catalytic system enables easy recovery and recycling as well as the use in multiple runs without loss of activity. The synthetic utility of this "green" methodology was further demonstrated by applying in bioactive and drug valued target syntheses.
- Geng, Pengxin,Tang, Yurong,Pan, Guanglong,Wang, Wentao,Hu, Jinchuan,Cai, Yunfei
-
supporting information
p. 6116 - 6122
(2019/11/20)
-
- MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS
-
Provided herein are antibacterial compounds, wherein the compounds in some embodiments have broad spectrum bioactivity. In various embodiments, the compounds act by inhibition of bacterial type 1 signal peptidase (SpsB), an essential protein in bacteria. Pharmaceutical compositions and methods for treatment using the compounds described herein are also provided.
- -
-
Paragraph 00751
(2018/09/12)
-
- INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL
-
The present invention provides compounds of Formula Ia and the pharmaceutically acceptable salts thereof, which are inhibitors of the ROMK (Kir1.1) channel. The compounds may be used as diuretic and/or natriuretic agents and for the therapy and prophylaxis of medical conditions including cardiovascular diseases such as hypertension, heart failure and conditions associated with excessive salt and water retention.
- -
-
Paragraph 0091
(2016/10/06)
-
- INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL
-
The present invention provides compounds of Formula (I) (Formula (I)) including pharmaceutically acceptable salts thereof, which are inhibitors of the ROMK (Kir1.1) channel. The compounds may be used as diuretic and/or natriuretic agents and for the therapy and prophylaxis of medical conditions including cardiovascular diseases such as hypertension, heart failure and chronic kidney disease and conditions associated with excessive salt and water retention.
- -
-
Page/Page column 29-30; 33
(2015/07/07)
-
- INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL
-
The present invention provides compounds of Formula(I) or a pharmaceutically acceptable salt thereof, which are inhibitors of the ROMK (Kir1.1) channel. The compounds may be used as diuretic and/or natriuretic agents and for the therapy and prophylaxis of medical conditions including cardiovascular diseases such as hypertension, heart failure, kidney disease, edema, and conditions associated with excessive salt and water retention.
- -
-
Page/Page column 73
(2014/09/03)
-
- INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL
-
The present invention provides compounds of Formula I and the pharmaceutically acceptable salts thereof, which are inhibitors of the ROMK (Kirl.1) channel. The compounds may be used as diuretic and/or natriuretic agents and for the therapy and prophylaxis of medical conditions including cardiovascular diseases such as hypertension, heart failure and conditions associated with excessive salt and water retention.
- -
-
Page/Page column 37
(2014/07/08)
-
- INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL
-
The present invention provides compounds of Formula Ia and the pharmaceutically acceptable salts thereof, which are inhibitors of the ROMK (Kir1.1) channel. The compounds may be used as diuretic and/or natriuretic agents and for the therapy and prophylaxis of medical conditions including cardiovascular diseases such as hypertension, heart failure and conditions associated with excessive salt and water retention.
- -
-
Page/Page column 33; 34
(2013/03/26)
-
- INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL
-
This invention relates to compounds of Formula I-VI having the following general structure: wherein R is a 6-8 membered saturated heterocyclic ring having 2 Nitrogen atoms connected with (CH2)n1- and (CH2)n2-, respectively, and pharmaceutically acceptable salts thereof which are inhibitors of the Renal Outer Medullary Potassium (ROMK) channel (Kir1.1). The compounds are useful as diuretics and natriuretics and therefore are useful for the therapy and prophylaxis of disorders resulting from excessive salt and water retention, including cardiovascular diseases such as hypertension and chronic and acute heart failure.
- -
-
Page/Page column 58
(2013/05/22)
-
- INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL
-
The present invention provides compounds of Formula (I) and the pharmaceutically acceptable salts thereof, which are inhibitors of the ROMK (Kir 1.1) channel. The compounds act as diuretics and natriuretics and are valuable pharmaceutically active compounds for the therapy and prophylaxis of medical conditions including cardiovascular diseases such as hypertension and conditions resulting from excessive salt and water retention.
- -
-
Page/Page column 53
(2013/05/21)
-
- INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL
-
The present invention provides compounds of Formula (I) and the pharmaceutically acceptable salts thereof, which are inhibitors of the ROMK (Kir1.1) channel. The compounds act as diuretics and natriuretics and are valuable pharmaceutically active compounds for the therapy and prophylaxis of medical conditions including cardiovascular diseases such as hypertension and conditions resulting from excessive salt and water retention.
- -
-
Page/Page column 35; 36
(2013/07/05)
-
- Structure-reactivity relationships in (2-hydroxyethyl)benzophenone photoremovable protecting Groups
-
A detailed study of substituent effects on the photochemical conversion of esters of (2-hydroxyethyl)benzophenone to the carboxylic acid was performed with the aim of improving on the reactivity of the parent, which was first reported decades ago. Over 20
- Pirrung, Michael C.,Roy, Biswajit Gopal,Gadamsetty, Surendra
-
supporting information; experimental part
p. 3147 - 3151
(2010/05/18)
-
- Enzymatic Baeyer-Villiger oxidation of Benzo-Fused ketones: Formation of regiocomplementary lactones
-
Baeyer-Villiger monooxygenases (BVMOs) are enzymes that are known to catalyse the Baeyer-Villiger oxidation of ketones in aqueous media using O2 as oxidant. Herein, we describe the oxidation of a set of diverse benzo-fused ketones by three different BVMOs
- Rioz-Martinez, Ana,De Gonzalo,Torres Pazmino, Daniel E.,Fraaije, Marco W.,Gotor, Vicente
-
supporting information; experimental part
p. 2526 - 2532
(2009/09/25)
-